GSK Says Breast Cancer Drug Approved by European Regulators

by Rajshri on  June 13, 2008 at 1:16 PM Drug News
RSS Email Print This Page Comment
GlaxoSmithKline has announced that European regulators have given marketing approval for its breast cancer drug Tykerb.
 GSK Says Breast Cancer Drug Approved by European Regulators
GSK Says Breast Cancer Drug Approved by European Regulators

"GlaxoSmithKline announced today that the European Commission has granted a conditional marketing authorisation for Tyverb ... for all 27 European Union member states," GSK said in a statement.

The decision came after the European Medicines Agency (EMEA) granted a "positive opinion" on Tyverb in December.

The drug, which is sold under the name Tykerb in the United States, is recommended for patients with advanced or metastatic breast cancer.

The treatment contains a molecule, administered orally, that works by getting inside the cancer cell and inhibiting two receptor proteins -- known as ErbB1 and ErbB2 -- that are partly responsible for tumour growth.

Source: AFP
RAS/M

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Women and Cancer Drug Toxicity Breast Biopsy Iodine Deficiency Disorder Pagets disease of the breast Mastitis Cancer and Homeopathy Signature Drug Toxicity Breast Cancer Facts Cancer Facts 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.


Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive